Table 3.
Associations between the change in GDF15 levels from rounds 1 to 3 and the change in biomarkers of organ function
| Individual analysesa | Fully adjusted modelb | |||||
|---|---|---|---|---|---|---|
| B-estimate | 95% CI | p-value | B-estimate | 95% CI | p-value | |
| ΔCRPround3-round1 (mg/L) | 0.011 | (0.009–0.013) | < 0.0001 | 0.007 | (0.005 – 0.009) | < 0.0001 |
| Δcystatin C round3-round1 (mg/L) | 0.881 | (0.811–0.952) | < 0.0001 | 0.656 | (0.569 – 0.743) | < 0.0001 |
| ΔeGFRround3-round1 (mL/min/1.73m2) | −0.008 | (−0.009–−0.007) | < 0.0001 | −0.004 | (−0.005–−0.003) | < 0.0001 |
| ΔASTround3-round1 (U/L) | 0.003 | (0.003–0.004) | < 0.0001 | 0.000 | (0.000 – 0.001) | 0.279 |
| ΔGGTround3-round1 (U/L) | 0.001 | (0.001–0.001) | < 0.0001 | 0.001 | (0.001–0.001) | < 0.0001 |
| Δhs-cTnIround3-round1 (ng/L) | 0.004 | (0.002–0.006) | < 0.0001 | 0.001 | (−0.000–0.003) | 0.101 |
aEach covariate was tested individually in a model adjusted for baseline levels of the covariate at round 1, GDF15 levels at round 1, age, sex, smoking, BMI, cholesterol, and cardiovascular diagnosis, hypertension diagnosis, diabetes diagnosis
bThe fully adjusted model included the baseline levels and change in level of all the biomarkers listed in the table, GDF15 levels at round 1, age, sex, smoking, and cardiovascular diagnosis, hypertension diagnosis, diabetes diagnosis.
AST, aspartate transaminase; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; hs-cTnI, high-sensitive troponin I; GGT, gamma-glutamyl transferase